Benzinga · Aug 21, 2026
OS Therapies Enters Open Market Sale Agreement With Jefferies; May Offer Common Stock Up To $75M Through Jefferies
-SEC Filing
OS
NYSE · OSTX
OS Therapies Incorporated
Healthcare · Biotechnology
$1.88
Down-$0.07 (-3.46%)
Updated Sep 8, 2026, 5:34 PM
SID Score
5.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 71.66M
- P/E ratio
- -0.01
- Dividend yield
- 0.00%
- 52-week range
- $1.15 – $2.35
- Volume
- 982.58K
- Avg. volume
- 342.06K
Price performance
OSTX price history
1M range · 0 trading sessions · Daily adjusted prices
OSTX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest OSTX news
The latest Smart Investors Daily articles mentioning OSTX.
Stock researchCompany · Overview
OSTX research
Overview
Company profile and research snapshot.
Company profile
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $13.01
- Implied upside
- —
- Analysts
- 10
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 9, 2026 | Roth Capital | Buy | — |
| May 19, 2026 | Lake Street | Buy | — |
| Apr 30, 2026 | D. Boral Capital | Buy | — |
| Apr 8, 2026 | D. Boral Capital | Buy | — |
| Mar 27, 2026 | D. Boral Capital | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 17, 2026
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Up to $10 million debt financing supported by U.K. subsidiary VAT refunds and reimbursable R&D tax credits, including $5 million funded at the August 10, 2026 first closingFDA Type C Statistical Methods Meeting mid-September 2026 meeting to review 2.5-year Overall Survival data and confirmatory Phase 3 trial design to gain alignment on statistical analysis plan for BLA submission under the Accelerated Approval ProgramInterim 3-year Overall Survival data expected in early September 2026 ahead of.
Yahoo · Aug 13, 2026
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma
Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September, 2026Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling Review expected following this meetingSustained overall survival benefit observed between 2-year and 2.5-year timepointsU.K. MHRA Statistical Methods Scientific Advice Meeting granted in parallelNew York, New York and Rockville, Maryland--(Newsfile Corp. - August 13, 2026) - OS...
Benzinga · Aug 13, 2026
FDA Grants OS Therapies’ Requested Type C Statistical Methods Meeting To Review 2.5-Yr Overall Survival Data From Phase 2b Trial Of OST-HER2 In Prevention Of Recurrence In Pulmonary Metastatic Osteosarcoma; Meeting To Occur In Mid-September
Meeting to occur in mid-September 2026Interim 3-year Overall Survival data expected early September, 2026Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
